IP Verse

Intranasal Pharmaceutical Dosage Forms Comprising Naloxone - EP2706982

The patent EP2706982 was granted to Euro Celtique on Mar 10, 2021. The application was originally filed on May 11, 2012 under application number EP12721507A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2706982

EURO CELTIQUE
Application Number
EP12721507A
Filing Date
May 11, 2012
Status
Patent Maintained As Amended
Feb 5, 2021
Grant Date
Mar 10, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MATHYS & SQUIREOct 1, 2018BOOTHWITHDRAWN

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTCN1575795
INTERNATIONAL-SEARCH-REPORTWO0062757
INTERNATIONAL-SEARCH-REPORTWO8203768
OPPOSITIONCN1575795
OPPOSITIONWO0062757
OPPOSITIONWO8203768
OTHERCN1575795
OTHERUS2006009447
OTHERWO0062757
OTHERWO8203768

Non-Patent Literature (NPL) Citations (46) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- Debra Kerr ET AL, "Intranasal naloxone for the treatment of suspected heroin overdose", ADDICTION, GB, (20080301), vol. 103, no. 3, doi:10.1111/j.1360-0443.2007.02097.x, ISSN 0965-2140, pages 379 - 386, XP055246395
OPPOSITION- "5.7 nasal powder drug delivery", Jelena Filipovic grcic et al, Pharmaceutical Manufacturing Handbook, (20080000), pages 651 - 681-
OPPOSITION- "5.7 nasal powder drug delivery", Jelena Filipovic grcic et al, Pharmaceutical Manufacturing Handbook, (20080000), pages 651 - 681, XP055523742-
OPPOSITION- BARTON et al., "Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting", The Journal of Emergency Medicine, (20050000), vol. 29, no. 3, pages 265 - 271-
OPPOSITION- BEHL et al., "Effects of physicochemical properties and other factors on systemic nasaldrug delivery", Advanced Drug Delivery Reviews, (19980000), vol. 29, pages 89 - 116-
OPPOSITION- "chapter 1 Food and Drugs administartion department of health and human services", Code of Federal Regulations, (20090401), pages 3-4,186 - 200-
OPPOSITION- "chapter 1 Food and Drugs administartion department of health and human services", Code of Federal Regulations, (20090401), pages 3-4,186 - 200, XP055523783-
OPPOSITION- Curriculum Vitae of Prof. Sveinbjörn Gizurarson-
OPPOSITION- DOE-SIMKINS et al., "Saved by the Nose: Bystander-Administered Intranasal Naloxone Hydrochloride for Opioid Overdose", American Journal of Public Health, (20090000), vol. 99, no. 5, pages 788 - 791-
OPPOSITION- DOWLING et al., "Population Pharmacokinetics of Intravenous, Intramuscular, and Intranasal Naloxone in Human Volunteers", Ther Drug Monit, (20080800), vol. 30, no. 4, pages 490 - 496-
OPPOSITION- DOWLING et al., "Population Pharmacokinetics of Intravenous, Intramuscular, and Intranasal Naloxone in Human Volunteers", Ther Drug Monit, (20080800), vol. 30, no. 4, pages 490 - 496, XP055523733-
OPPOSITION- English language machine translation of D27-
OPPOSITION- English language machine translation of D3-
OPPOSITION- Expert Declaration of Prof. Sveinbjörn Gizurarson-
OPPOSITION- GIZURARSON, S. et al., "Animal models for intranasal drug delivery studies: A review article", Acta Pharm Nord., (19900200), vol. 2, no. 2, pages 105 - 122-
OPPOSITION- GIZURARSON, S. et al., "Animal models for intranasal drug delivery studies: A review article", Acta Pharm Nord., (19900200), vol. 2, no. 2, pages 105 - 122, XP055524098-
OPPOSITION- HUSSAIN et al., "Nasal absorption of naloxone and buprenorphine in rats", International Journal of Pharmaceutics, (19840000), vol. 21, pages 233 - 237-
OPPOSITION- KERR et al., "Intranasal naloxone for the treatment of suspected heroin overdose", Addiction, (20080000), vol. 103, pages 379 - 386-
OPPOSITION- KERR et al., "Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose", Addiction, (20090000), vol. 104, pages 2067 - 2074-
OPPOSITION- LOIMER et al., "Nasal administration of naloxone for detection of opiate dependence", J. psychiatry. Res., (19920000), vol. 26, no. 1, pages 39 - 43-
OPPOSITION- MCDONALD et al., "Comprehensive Review International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database", Drug and Alcohol Review, (20170421), pages 1 - 11, (20170608), XP055524055-
OPPOSITION- MIDDLETON et al., "The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers", Addiction, (20110503), vol. 106, no. 8, pages 1460 - 1473-
OPPOSITION- "naloxone hydrochloide", HASSAN et al., Analytical Profiles of Drug Substances, (19850000), vol. 14, pages 454 - 489-
OPPOSITION- "naloxone hydrochloide", HASSAN et al., Analytical Profiles of Drug Substances, (19850000), vol. 14, pages 454 - 489, XP055524063-
OPPOSITION- "Naloxone Hydrochloride 400 micrograms/ml solution for injection PL 19364/0031", MHRA, pages 1 - 21-
OPPOSITION- "Naloxone hydrochloride dihydrate Product Number N7758", Sigma, (20051227), page 1-
OPPOSITION- "Naloxone hydrochloride dihydrate Product Number N7758", Sigma, (20051227), page 1, XP055524078-
OPPOSITION- OLA DALE, "Nesen-mer enn til a snyte seg i", Tidsskr Nor. Legeforen, (20100000), vol. 130, no. 13-14, page 1326-
OPPOSITION- OLA DALE, "Nesen-mer enn til a snyte seg i", Tidsskr Nor. Legeforen, (20100000), vol. 130, no. 13-14, page 1326, XP055524113-
OPPOSITION- SAHIN-YILMAZ et al., "Anatomy and Physiology of the Upper Airway", Proc Am Thorac Soc, (20110000), vol. 8, pages 31 - 39-
OPPOSITION- SAHIN-YILMAZ et al., "Anatomy and Physiology of the Upper Airway", Proc Am Thorac Soc, (20110000), vol. 8, pages 31 - 39, XP055524051-
OPPOSITION- Screen Print evidencing date of online availability of D8-
OPPOSITION- "The nasal mucosa", Donald F et al, THE NOSE, (19820000), pages 167 - 168-
OPPOSITION- "The nasal mucosa", Donald F et al, THE NOSE, (19820000), pages 167 - 168, XP055523797-
OPPOSITION- WERMELING, D. P. et al., "A response to the opioid overdose epidemic: naloxone nasal spray", Drug Deliv Transl Res., (20130200), vol. 3, no. 1, pages 63 - 74-
OPPOSITION- WERMELING, D. P., "Opioid Harm Reduction Strategies: Focus on Expanded Access to Intranasal Naloxone", Pharmacotherapy, (20100000), vol. 30, no. 7, pages 627 - 631-
OPPOSITION- WERMELING, D. P. et al., "A response to the opioid overdose epidemic: naloxone nasal spray", Drug Deliv Transl Res., (20130200), vol. 3, no. 1, pages 63 - 74, XP055501576
OPPOSITION- LOIMER et al., "Nasal administration of naloxone for detection of opiate dependence", J. psychiatry. Res., (19920000), vol. 26, no. 1, pages 39 - 43, XP055523727
OPPOSITION- HUSSAIN et al., "Nasal absorption of naloxone and buprenorphine in rats", International Journal of Pharmaceutics, (19840000), vol. 21, pages 233 - 237, XP023844897
OPPOSITION- BARTON et al., "Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting", The Journal of Emergency Medicine, (20050000), vol. 29, no. 3, pages 265 - 271, XP005089424
OPPOSITION- BEHL et al., "Effects of physicochemical properties and other factors on systemic nasaldrug delivery", Advanced Drug Delivery Reviews, (19980000), vol. 29, pages 89 - 116, XP055523768
OPPOSITION- KERR et al., "Intranasal naloxone for the treatment of suspected heroin overdose", Addiction, (20080000), vol. 103, pages 379 - 386, XP055246395
OPPOSITION- KERR et al., "Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose", Addiction, (20090000), vol. 104, pages 2067 - 2074, XP002660417
OPPOSITION- MIDDLETON et al., "The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers", Addiction, (20110503), vol. 106, no. 8, pages 1460 - 1473, XP055356809
OPPOSITION- WERMELING, D. P., "Opioid Harm Reduction Strategies: Focus on Expanded Access to Intranasal Naloxone", Pharmacotherapy, (20100000), vol. 30, no. 7, pages 627 - 631, XP055523751
OPPOSITION- DOE-SIMKINS et al., "Saved by the Nose: Bystander-Administered Intranasal Naloxone Hydrochloride for Opioid Overdose", American Journal of Public Health, (20090000), vol. 99, no. 5, pages 788 - 791, XP055523766

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents